New hope for bladder cancer patients: experimental drug combo aims to beat chemo
NCT ID NCT07424287
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial is testing whether a combination of an experimental drug (SHR-1501) plus the standard immunotherapy BCG works better than chemotherapy for people with a type of bladder cancer (papillary-only NMIBC) that no longer responds to BCG alone. The study plans to enroll 236 adults who have had all visible tumors removed. The main goal is to see how long the cancer stays away. The trial is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1501 (an experimental drug) combined with BCG (a standard immunotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with bladder cancer that no longer responds to BCG alone, potentially delaying or avoiding the need for bladder removal.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The experimental combination may not be more effective than chemotherapy, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMIBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School
Shanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact